The regulatory risks of AI in medical communications are significant and, in 2026, still largely unresolved. AI-generated content in pharma and healthcare sits at the intersection of multiple overlapping frameworks: medicines advertising codes, data protection law, and emerging AI-specific regulation — none of which were designed with generative AI explicitly in mind. The result is a compliance environment where the rules exist but their application is ambiguous, and where the consequences of getting it wrong can be severe. This article works through the most pressing questions facing medical affairs, regulatory, and communications teams right now.
Which regulations currently govern AI-generated medical content?
No single regulation specifically governs AI-generated medical content, but several overlapping frameworks apply. In the UK, the ABPI Code of Practice, the Human Medicines Regulations 2012, and MHRA advertising guidance all regulate promotional and non-promotional communications about medicines, regardless of how that content was produced. The fact that AI generated a piece of copy does not exempt it from these requirements.
In the EU, the picture is further complicated by the EU AI Act, which came into force in 2024 and classifies certain AI applications in healthcare as high-risk systems subject to conformity assessments and transparency obligations. Medical content that influences clinical decision-making or patient behaviour could fall within this classification, depending on how it is used and by whom.
In the United States, the FDA’s existing guidance on promotional labelling and advertising applies to AI-generated content, and the agency has signalled increasing scrutiny of how AI tools are used in drug promotion. FDA draft guidance on digital health and AI continues to evolve, and companies operating across markets need to monitor all three regulatory environments simultaneously.
The practical implication: AI-generated medical content is not operating in a regulatory vacuum. It is operating in a regulatory environment built for human-authored content, which creates ambiguity rather than absence of rules. That ambiguity is itself a risk.
What happens when AI-generated medical content is inaccurate or misleading?
When AI-generated medical content is inaccurate or misleading, the regulatory and reputational consequences fall on the company that published it — not on the AI system that produced it. Regulatory bodies do not recognise AI as a responsible party. Under the ABPI Code, the MHRA’s advertising rules, and equivalent frameworks in other markets, accountability sits with the pharmaceutical company and, where relevant, its agency partners.
The specific risks include formal complaints to the PMCPA, MHRA enforcement action, mandatory withdrawal of materials, and reputational damage affecting relationships with healthcare professionals, payers, and patients. In the most serious cases, misleading promotional content can trigger regulatory investigations that extend well beyond the individual piece of content in question.
AI systems are known to hallucinate — producing confident, fluent outputs that are factually incorrect. In a general marketing context, that is an inconvenience. In medical communications, where a misquoted clinical trial result or an inaccurate efficacy claim could influence prescribing decisions or patient understanding, the stakes are fundamentally different. The speed at which AI can generate content does not reduce the obligation to verify every claim against source data before publication.
This is why robust human oversight is not optional in medcomms. Medical writers, regulatory reviewers, and medical affairs professionals must remain actively involved in reviewing AI-assisted outputs — not as a formality, but as a genuine quality control step with documented sign-off.
How does AI affect medical-legal-regulatory review processes?
AI affects medical-legal-regulatory (MLR) review in two ways simultaneously: it can accelerate content production, increasing the volume of materials entering the review queue, and it can introduce new types of errors that are harder to detect than those typically made by human writers. Both effects increase pressure on MLR teams rather than relieving it.
The volume problem is real. When AI tools allow a team to draft ten versions of a piece of content in the time it previously took to draft two, the MLR function must either expand its capacity or accept longer review cycles. Neither outcome reduces risk, and neither is cost-neutral.
The error detection problem is subtler. AI-generated text tends to be grammatically fluent and structurally coherent, which can make errors less visually obvious than the drafting mistakes a human writer might make. A hallucinated citation, a subtly misrepresented clinical endpoint, or a claim that is technically accurate but contextually misleading can pass initial review if reviewers are not specifically trained to interrogate AI outputs with the same rigour they apply to primary source documents.
Some organisations are exploring AI-assisted MLR tools that cross-reference claims against approved label language or published data. These have genuine potential, but they introduce their own validation requirements — particularly under the EU AI Act’s provisions for high-risk AI systems in healthcare. The governance of the review tool itself becomes a compliance question.
What are the data privacy risks of using AI in medical communications?
The data privacy risks centre on two issues: the nature of the data being input into AI systems, and the data handling practices of the AI platforms themselves. Both require careful assessment before any AI tool is deployed in a medcomms workflow.
Medical communications frequently involves sensitive information: unpublished clinical data, patient case studies, healthcare professional contact details, market access submissions, and commercially confidential strategy documents. When this material is entered into a generative AI tool, questions immediately arise about where that data is stored, whether it is used to train the model, who else might have access to it, and whether the platform’s terms of service are compatible with GDPR obligations or equivalent frameworks in other markets.
Under UK GDPR and the EU GDPR, organisations processing personal data must have a lawful basis for doing so and must ensure that any third-party processors meet the same data protection standards. Many commercial AI platforms are headquartered in the United States, which creates additional complexity around international data transfers — particularly given the legal uncertainty that has characterised EU-US data transfer frameworks in recent years.
The practical guidance is straightforward, even if implementation is not: before using any AI tool in a medcomms context, legal and compliance teams should conduct a thorough data processing impact assessment, review the platform’s data use terms explicitly, and establish clear internal policies about what categories of information may and may not be entered into AI systems.
Should pharma companies use AI for medical communications right now?
Yes — but with clearly defined governance in place before deployment, not after. The question in 2026 is not whether to use AI in medical communications (the efficiency and capability arguments are too strong to ignore indefinitely), but where, how, and under what controls it is appropriate to do so.
There are medcomms applications where AI offers genuine value with manageable risk: literature searches and evidence synthesis support, first-draft generation for internal briefing documents, translation workflows with human review, and formatting or structural tasks that do not involve clinical claims. These are lower-risk entry points that allow teams to build familiarity with AI tools and develop internal governance frameworks before expanding use.
There are also applications where the risk profile remains high and where human expertise should remain primary: promotional content subject to ABPI or FDA review, patient-facing materials, clinical study reports, and any content that makes efficacy or safety claims. In these areas, AI can play a supporting role, but the intellectual and regulatory responsibility must remain with qualified human professionals.
The companies that will navigate this well are those that treat AI governance as a strategic capability rather than an afterthought — with documented policies, trained teams, clear escalation paths, and regular review of how the regulatory landscape is evolving. Because it is still evolving rapidly.
How we approach AI in medical communications
We work with pharmaceutical companies, biotech organisations, and healthcare charities to produce medical communications that are scientifically rigorous, strategically sharp, and creatively distinctive. On AI, our position is grounded in practical experience rather than uncritical enthusiasm or blanket caution.
- All medcomms work is developed within relevant client governance, industry codes, and applicable regulatory requirements across the markets where we operate
- Human medical writers, strategists, and regulatory-aware creatives remain central to every project — AI does not replace the expertise that makes communications both accurate and effective
- Where AI tools are used to support workflow efficiency, their outputs are subject to the same rigorous review processes applied to all content
- We treat regulatory compliance and creative ambition as complementary priorities, not competing ones
If your organisation is working through how to integrate AI responsibly into medical communications workflows — or if you need a partner who can deliver communications that are accurate, ambitious, and compliant — speak to the Wizzard team to find out how we can help.
Content is for general information and communications purposes and does not constitute medical, clinical, legal or regulatory advice. Work is developed within relevant client governance, industry codes and applicable regulatory requirements in the countries and markets where Wizzard operates.